Evidence map›Paper›PMID 40347249›Full record

Trial reportAnnals of hematology2025

Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP.

Lijun Fang, Ting Sun, Hu Zhou, Guitao Jie, Jiaping Fu, Enqin Yang, Zeping Zhou, Ligen Liu, Jingyu Zhang, Shenxian Qian and 7 more

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lijun FangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin & CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Ting SunState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin & CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Hu ZhouThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450000, China.
Guitao JieLinyi Central Hospital, Linyi, 276000, China.
Jiaping FuShaoxing People's Hospital, Shaoxing, 312000, China.
Enqin YangPeople's Hospital of Rizhao, Rizhao, 276800, China.
Zeping ZhouThe Second Affiliated Hospital of Kunming Medical University, Kunming, 650000, China.
Ligen LiuTong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China.
Jingyu ZhangThe Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Shenxian QianAffiliated Hangzhou Frist Peoples Hospital, School of Medicine, Westlake University, Hangzhou, 310000, China.
Yun ChenCentral Hospital Affiliated to Shandong First Medical University, Jinan, 250000, China.
Ling LiuThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Jian GuNorthern Jiangsu People's Hospital, Yangzhou, 225000, China.
Fanliang KongThe Second People's Hospital of Hefei, Hefei, 230000, China.
Ruibin HuangThe First Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
Yunfei ChenState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin & CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. chenyunfei@ihcams.ac.cn.
Lei ZhangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin & CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. zhanglei1@ihcams.ac.cn.

Funding

National Natural Science Foundation of China 82104618
6 · The paper itself

Abstract

A prospective, single-arm, open-label Phase III clinical trial was conducted across multiple centers in China from April 27, 2020, to June 15, 2021, to assess the efficacy and safety of 10% intravenous immunoglobulin (IVIg) in treating adult immune thrombocytopenic purpura (ITP). Within 7 days of treatment initiation, the 10% IVIg group exhibited an overall response rate of 87.0%, with 32 patients (46.4%) achieving complete response and 28 patients (40.6%) demonstrating partial response, comparable to the 5% IVIg group. Notably, the median time to achieve a platelet count (PLT) of 50 × 10

Indexed as

Immunoglobulins, IntravenousPurpura, Thrombocytopenic, IdiopathicAdultAgedChinaFemaleHumansMaleMiddle AgedPlatelet CountProspective StudiesTreatment OutcomeYoung AdultImmunoglobulins, IntravenousClinical trialEfficacy and safetyImmune thrombocytopenic purpuraIntravenous immunoglobulin (IVIg)

Identifiers

PMID40347249
PMCPMC12141155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.